Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial - Matthew Matasar; Zhiming Li; Theodoros P. Vassilakopoulos; Juan-Manuel Sancho; Andreas Viardot; Andrew McMillan; Mehmet Sinan Dal; Juliana Pereira; Jin Seok Kim; Lugui Qiu; Connie Lee Batlevi; Rania Ibrahim; et al. (Journal of Clinical Oncology, 2026)